Evidence map›Paper›PMID 40666481›Full record

ArticleACS medicinal chemistry letters2025

Advancing Isotope Labeling Technologies at AstraZeneca through Academic-Industrial Collaboration.

Ryan A Bragg, Jonas Bergare, Markus Artelsmair, William J Kerr, Troels Skrydstrup, Charles S Elmore

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. An IntegratedACS catalysis · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ryan A BraggEarly Chemical Development, Pharmaceutical Science, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Jonas BergareEarly Chemical Development Pharmaceutical Science, R&D, AstraZeneca, Gothenburg 431 83, Sweden.
Markus ArtelsmairEarly Chemical Development Pharmaceutical Science, R&D, AstraZeneca, Gothenburg 431 83, Sweden.
William J KerrDepartment of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow, Scotland G1 1XL, U.K.ORCID https://orcid.org/0000-0002-1332-785X
Troels SkrydstrupInterdisciplinary Nanoscience Center (iNANO), Department of Chemistry, Aarhus University, Gustav Wieds Vej 14, 8000 Aarhus C, Denmark.ORCID https://orcid.org/0000-0001-8090-5050
Charles S ElmoreEarly Chemical Development Pharmaceutical Science, R&D, AstraZeneca, Gothenburg 431 83, Sweden.ORCID https://orcid.org/0000-0001-7434-8307

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Academic-Industrial collaborations have played an important role in developing new synthetic methodologies for the isotope chemistry team at AstraZeneca. In this viewpoint, we present the outcome of two collaborations and illustrate how the innovative methodologies developed through these partnerships have been effectively applied within an AstraZeneca project.

Indexed as

CarbonylationCollaborationIsotopesRadiolabelingTritium

Identifiers

PMID40666481
PMCPMC12257393

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.